MYLAN INSTITUTIONAL LLC

Mylan Institutional LLC specializes in the manufacturing of pharmaceutical preparations, with a focused capability in producing drugs, hematological agents, and related therapeutic products for federal healthcare systems. The company’s technical expertise lies in GMP-compliant pharmaceutical formulation, batch manufacturing, quality control systems, and regulatory-compliant packaging for institutional use. Their work supports the reliable, large-scale production of critical medications used in clinical and long-term care settings, with an emphasis on consistency, sterility, and adherence to FDA and VA pharmacopeial standards. A key differentiator is their ability to deliver complex pharmaceutical formulations under strict institutional supply chain protocols, ensuring timely availability for patient care environments. The contractor has demonstrated direct experience supporting the Department of Veterans Affairs, providing pharmaceutical products under Federal Supply Schedule contracts designed for VA medical centers and veterans’ health services. This relationship reflects a specialized alignment with VA’s requirements for bulk drug procurement, formulary compliance, and distribution to veteran-facing healthcare facilities. Their work supports the VA’s mission to ensure uninterrupted access to essential medications across its nationwide network. Mylan Institutional LLC operates primarily under NAICS 325412, which encompasses the manufacturing of finished pharmaceutical dosage forms such as tablets, injectables, and oral solutions. Their market positioning centers on institutional-grade pharmaceutical supply, serving government healthcare systems that require high-volume, low-variability drug production with rigorous documentation and traceability. They are not positioned for retail or specialty pharmacy markets but rather for bulk, institutional procurement channels. As a ZZ-structured entity headquartered in Morgantown, West Virginia, the company operates without active federal certifications such as 8(a), HUBZone, or SDVOSB. Its government market presence is narrowly focused on pharmaceutical manufacturing for federal health agencies, with no public indication of broader geographic or multi-agency diversification beyond its VA contract history.